Ann: Board and Management Changes , page-5

Thanks Pitt, yeah was using an old financial report, so had the old %'s. Looks like Donnison hasn't sold any yet, and should he look to sell, I'm guessing the 2% would be easily consumed given the demand seen the past few weeks.

Viney, agree on it being a whole new company/direction, and the new executives do have pharmaceutical experience so is definitely not a downgrade. Also Lewis should keep things ticking along nicely in the mean-time.

My preference probably would've been for Donnison to bed down the changes fully before standing aside, but at least the new director will be getting to know the intricacies of the combined business from day 1.

Should be plenty more announcements in the short term to look forward to.